NCT05463822View on ClinicalTrials.gov

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions
Overactive BladderBladder, OveractiveUrge IncontinenceUrgency UrinaryUrinary Frequency/Urgency
Interventions
DRUG

Transvaginal botulinum toxin A (BTA) injection

Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.

Trial Locations (1)

94304

Urology Clinic (Stanford University), 1000 Welch Road, Suite 100, Stanford

All Listed Sponsors
collaborator

Society for Urodynamics & Female Urology Foundation

UNKNOWN

lead

Stanford University

OTHER

NCT05463822 - Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder | Biotech Hunter | Biotech Hunter